Changes to SEER Data Set for Scope of Regional Lymph Node Surgery

Similar documents
We re on the Web! Visit us at VOLUME 19 ISSUE 1. January 2015

NAACR Treatment Webinar Quiz 1

Patient Identification Quiz

This section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard

Alternate Name Item # Length Source of Standard Column # Alternate Name Item # Length Source of Standard Column #

INTRODUCTION TO CANCER STAGING

STAGE CATEGORY DEFINITIONS

Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma

Prostate Case Scenario 1

Breast Surgery: Yesterday, Today and Tomorrow

UNMH Hematology/Oncology Clinical Privileges

NEW JERSEY STATE CANCER REGISTRY

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Breast Cancer. Saima Saeed MD

BREAST CANCER SURGERY. Dr. John H. Donohue

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

I.2 CNExT This section was software specific and deleted in 2008.

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]

Compassionate, team-driven cancer care CLOSE TO HOME.

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

OFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM

Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

NAACCR Webinar Series 1

THE SURVIVORSHIP EXPERIENCE IN PANCREATIC CANCER

Classification System

THE BREAST CENTER AT MONTEFIORE NYACK HOSPITAL

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

A Comprehensive Approach to. International Cancer Survival Benchmarking. SurvMark-2

14. Mucosal Melanoma of the Head and Neck

Complete breast care from the team that cares. Breast Center

Melanoma Quality Reporting

California Cancer Registry Production Automation and Quality Control Unit Data Alert - Registrar

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Clinical Pathological Conference. Malignant Melanoma of the Vulva

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Continuing Education Exam Pediatric Tumor Boards, Volume II

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

Chapter 2 Neoplasms C00-D49 November 11, Chapter 2: Neoplasms Category: C00-D49 Official Coding Guidelines: Section 1.C.2, p.

Table of contents. Page 2 of 40

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy

Northumbria Healthcare NHS Foundation Trust. Breast Sentinel Lymph Node Biopsy. Issued by the Breast Team

Part VIII Entering Information Into the Urology Report Form

47. Melanoma of the Skin

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

46. Merkel Cell Carcinoma

7/29/2014. Patterns of Care in Colon Cancer ( ) Literature. Background. Florida Cancer Data Compliance with NCCN Guidelines

SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING

VISUAL EDITING GUIDELINES March 2015 (revised June 2015)

Hodgkin's Lymphoma. Symptoms. Types

Obtaining the diagnosis:

Corporate Medical Policy

Requirements for Abstracted Text

Surgery for Breast Cancer

Melanoma Case Scenario 1

Corporate Medical Policy

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Characteristics, treatment patterns, and survival outcomes of primary GI melanoma cases compared to cutaneous melanoma, SEER:

Melanoma Case Scenario 1

Advances in Localized Breast Cancer

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Prostate Overview Quiz

FORDS to STORE: The Evolution of Cancer Registry Coding Frederick L. Greene, MD FACS Medical Director, Cancer Data Services Levine Cancer Institute

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Annual Report 2015 of the Certified Breast Cancer Centres (BCCs)

10. HPV-Mediated (p16+) Oropharyngeal Cancer

Cancer Endorsement Maintenance 2011-Maintenance Measures

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.

Yescarta (axicabtagene ciloleucel)

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

DAYS IN PANCREATIC CANCER

Pathology Student Interest Group. Sponsored by the College of American Pathologists

Innovations in Lung Cancer Diagnosis and Surgical Treatment

General Surgery Curriculum Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

Pharmacy Prior Authorization

Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

11/21/13 CEA: 1.7 WNL

Cancer , The Patient Education Institute, Inc. ocf80101 Last reviewed: 06/08/2016 1

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Different Types of Cancer

Corporate Medical Policy

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

Results of the ACOSOG Z0011 Trial

Acute: Symptoms that start and worsen quickly but do not last over a long period of time.

Transcription:

Changes to SEER Data Set for 2003 Scope of Regional Lymph Node Surgery Effective 1/1/2003. All primary sites will have the same coding structure for this field None No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy. 1 Biopsy or aspiration of regional lymph node, NOS Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease. 2 Sentinel lymph node biopsy Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body. Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor. 3 Number of regional nodes removed unknown or not stated; regional lymph nodes removed, NOS Sampling or dissection of regional lymph node(s) and the number of nodes removed is unknown or not stated. The procedure is not specified as sentinel node biopsy. 4 1-3 regional lymph nodes removed Sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy. 5 4 or more regional lymph nodes removed Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy. 6 Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 were performed,but timing was not stated in patient record. 7 Sentinel node biopsy and code 3, 4, or 5 at different times Code 2 was followed in a subsequent surgical event by procedure 3, 4, or 5. 9 Unknown or not applicable It is unknown whether regional lymph node surgery was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative or myeloproliferative disease.

Surgical Procedure of Other Site Effective 1/1/2003. All primary sites will have the same coding structure for this field This field records the surgical removal of regional tissues other than nodes, distant lymph nodes or other tissue(s)/organ(s) beyond the primary site. 0 None No surgical procedure of non-primary site was performed. Diagnosed at autopsy. 1 Non-primary surgical procedure performed Non-primary surgical resection to other site(s), unknown if whether the site(s) is regional or distant. Non-primary surgical procedure to other regional sites Resection of regional site. Note:for en bloc resection with primary site, see Surgery of Primary Site field. Do not code en bloc resection here. 3 Non-primary surgical procedure to distant lymph node(s) Resection ofdistant lymph node(s). 4 Non-primary surgical procedure to distant site Resection of distant site. Combination of codes Any combination of surgical procedures 2, 3, or 4. 9 Unknown It is unknown whether any surgical procedure of a non-primary site was performed. Death certificate only. 2

Chemotherapy Effective 1/1/2003. Chemotherapy field expanded to two digits with previous single digit codes left intact. Treatments (none or actual) in 00-09 range. Reasons treatment not administered in 80-89 range. Unknown is now 99. 00 None; chemotherapy was not part of the planned first course of therapy 01 Chemotherapy administered as first course therapy, but the type and number of agents is not documented in patient record. 02 Single-agent chemotherapy administered as first course therapy. 03 Multi-agent chemotherapy administered as first course therapy. 82 [new] Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age). 85 [new] Chemotherapy was not administered because the patient died prior to planned or recommended therapy. 86 [new] Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. 87 Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. 88 Chemotherapy was recommended, but it is unknown if it was administered. 99 It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

Hormone Therapy Effective 1/1/2003. Hormone Therapy field expanded to two digits with previous single digit codes left generally intact. Endocrine surgery and radiation moved to new Hematologic Transplant and Endocrine Procedures field Treatments (none or actual) in 00-09 range. Reasons treatment not administered in 80-89 range. Unknown is now 99. 00 None, hormone therapy was not part of the planned first course of therapy. 01 Hormone therapy administered as first course therapy. 82 [new] Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age). 85 [new] Hormone therapy was not administered because the patient died prior to planned or recommended therapy. 86 [new] Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. 87 Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. 88 Hormone therapy was recommended, but it is unknown if it was administered. 99 It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

Immunotherapy Effective 1/1/2003. Immunotherapy field expanded to two digits with previous single digit codes left generally intact. Bone marrow transplant and stem cell procedures moved to new Hematologic Transplant and Endocrine Procedures field Treatments (none or actual) in 00-09 range. Reasons treatment not administered in 80-89 range. Unknown is now 99. 00 None, immunotherapy was not part of the planned first course of therapy. 01 Immunotherapy administered as first course therapy. 82 [new] Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age). 85 [new] Immunotherapy was not administered because the patient died prior to planned or recommended therapy. 86 [new] Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient. record. 87 Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. 88 Immunotherapy was recommended, but it is unknown if it was administered. 99 It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only. 5

Hematologic Transplant and Endocrine Procedures NEW field effective 1/1/2003. Bone marrow and stem cell procedures are now coded in this field Endocrine surgery or radiation is now coded in this field Treatments (none or actual) in 00-30 range. Combination hematologic transplant and endocrine procedures coded as 40. Reasons treatment not administered in 80-89 range. Unknown is now 99. 00 No transplant procedure or endocrine therapy was administered as part of first course therapy. 10 A bone marrow transplant procedure was administered, but the type was not specified. 11 Bone marrow transplant-autologous. 12 Bone marrow transplant-allogeneic. 20 Stem cell harvest. 30 Endocrine surgery and/or endocrine radiation therapy. 40 Combination of endocrine surgery and/or radiation with a transplant procedure. (Combination of codes 30 with 10-20.) 82 Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age). 85 Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy. 86 Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record. 87 Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record. 88 Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered. 99 It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record. Death certificate only. 6